<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05086770</url>
  </required_header>
  <id_info>
    <org_study_id>NEXTBIO-UIGB-UF01</org_study_id>
    <nct_id>NCT05086770</nct_id>
  </id_info>
  <brief_title>Comparison of Pain After Uterine Artery Embolization Using Spherical Gelfoam or Tris-acryl Gelatin Microsphere</brief_title>
  <official_title>Comparison of Pain After Uterine Artery Embolization Using Spherical Gelfoam or Tris-acryl Gelatin Microsphere in Patients With Symptomatic Fibroids: A Prospective, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Next Biomedical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Next Biomedical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective and randomized investigation planned to compare pain after&#xD;
      uterine artery embolization using spherical gelfoam or tris-acryl gelatin microsphere in 60&#xD;
      patients with symptomatic fibroids.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This investigational study is designed to compare pain after uterine artery embolization&#xD;
      using spherical gelfoam or tris-acryl gelatin microsphere in patients with symptomatic&#xD;
      fibroids.&#xD;
&#xD;
      The primary end-points will be evaluated by assessing the maximum Visual Analogue Scale (VAS)&#xD;
      score obtained for each time points within 24 hours after embolization.&#xD;
&#xD;
      Secondary end-points consist of evaluating six items: 1) fentanyl and analgesic usage within&#xD;
      24 hours, 2) comparison of symptom severity score and health-related quality of life score,&#xD;
      3) comparison of postoperative inflammation, 4) assessment of tumor necrosis degree in&#xD;
      Magnetic Resonance Imaging, 5) fluoroscopy and procedure time comparison, and 6) assessment&#xD;
      of residual ovarian function before and after surgery (Serum AMH).&#xD;
&#xD;
      This study included patients between the ages of 20 and less than 60 years of age who were&#xD;
      diagnosed with uterine myoma and planned to undergo uterine artery embolization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity by numerical rating scale</measure>
    <time_frame>0-24 hours after embolization</time_frame>
    <description>0-10 numerical rating scale (0, no pain at all; 10, worst pain imaginable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fentanyl and analgesic usage volume</measure>
    <time_frame>24 hours</time_frame>
    <description>Fentanyl and analgesic usage volume within 24 hours after embolization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom severity score</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of symptom severity score before and 3 months after embolization&#xD;
Symptom was scored on a scale of 0-10, with 0 being no symptoms and 10 being the baseline, or initial symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative inflammation</measure>
    <time_frame>24 hours</time_frame>
    <description>Comparison of level or counts of C-Reactive Protein (CRP), leukocyte, neutrophil before and after embolization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor necrosis degree</measure>
    <time_frame>3 months</time_frame>
    <description>Assessment of tumor necrosis degree in MR after embolization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy and procedure time</measure>
    <time_frame>procedure time</time_frame>
    <description>Fluoroscopy and procedure time taken for embolization to achieved</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Anti-Mullerian Hormone (AMH)</measure>
    <time_frame>3 months</time_frame>
    <description>Residual ovarian function before and after embolization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Uterine Myoma</condition>
  <condition>Uterine Fibroid</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The test group will be administered 300-500 ㎛ range of Spherical Gelfoam (Nexsphere™). A suspension in which a contrast medium and physiological saline are mixed will be administered until the embolization is sufficiently achieved.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group will be administered 500-700 ㎛ of Embospheres until sufficient embolization is achieved.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spherical Gelfoam (Nexsphere™)</intervention_name>
    <description>Spherical Gelfoam (Nexsphere™) is a yellow powder, made of 100% hydrophilic gelatin. It is used to make a suspension by mixing a contrast agent and physiological saline. The indications for spherical gel foam are hepatic artery chemoembolization, uterine artery embolization, prostate artery embolization, and treatment of various hemorrhagic diseases. It physically embolizes blood vessels and is decomposed within 4-8 weeks after intravascular injection.</description>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Embosphere</intervention_name>
    <description>Tris-acryl gelatin microspheres (Embosphere Microspheres) are biocompatible and nonresorbable with cell adhesion properties for complete and durable mechanical occlusion.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A patient aged between 20 and under 60 who decided to undergo uterine artery&#xD;
             embolization for symptomatic uterine myoma.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bradycardia on electrocardiogram (&lt; 45 bpm)&#xD;
&#xD;
          -  Ventricular conduction abnormalities&#xD;
&#xD;
          -  Liver failure&#xD;
&#xD;
          -  Kidney failure&#xD;
&#xD;
          -  Uncontrolled high blood pressure&#xD;
&#xD;
          -  Obesity (BMI ≥ 30 ㎏/㎡)&#xD;
&#xD;
          -  Patients who are allergic to drugs&#xD;
&#xD;
          -  Patients who cannot read consent forms such as illiterate or foreigners&#xD;
&#xD;
          -  Pregnant woman&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Man Deuk Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin Hee Maeng, MS</last_name>
    <phone>82-32-880-0860</phone>
    <email>jhmaeng@nextbiomedical.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Man Deuk Kim, MD, PhD</last_name>
      <phone>82-1599-1004</phone>
      <email>mdkim@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gelatin Sponge, Absorbable</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

